Atlas Trials

Hangzhou Sumgen Biotech Co., Ltd.

11 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Hangzhou Sumgen Biotech Co., Ltd.

RecordFirmDate
Study of SG301 for Renal AMR After Transplantation (NCT07764627)Hangzhou Sumgen Biotech Co., Ltd.2026-09-01
SG301-SC Injection Safety Study in Subjects With Primary ITP Patients (NCT07710248)Hangzhou Sumgen Biotech Co., Ltd.2026-06-11
To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma (NCT07454187)Hangzhou Sumgen Biotech Co., Ltd.2026-04-16
To Evaluate the Efficacy and Safety of SG301 SC Injection in Systemic Lupus Erythematosus (NCT07447986)Hangzhou Sumgen Biotech Co., Ltd.2026-03-26
A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients (NCT06508983)Hangzhou Sumgen Biotech Co., Ltd.2024-06-14
SG2918 For Advanced Malignant Tumors (NCT06167486)Hangzhou Sumgen Biotech Co., Ltd.2023-12-26
SG301-SC Injection Safety Study in Subjects With Systemic Lupus Erythematosus (NCT06144710)Hangzhou Sumgen Biotech Co., Ltd.2023-11-10
An Open-label Study of SG1827 in Subjects With Advanced Solid Tumors (NCT06076291)Hangzhou Sumgen Biotech Co., Ltd.2023-09-27
SG2501 Safety Study in Subjects with Relapsed or Refractory Hematological Malignancies and Lymphoma. (NCT05293912)Hangzhou Sumgen Biotech Co., Ltd.2023-03-03
SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies (NCT04684108)Hangzhou Sumgen Biotech Co., Ltd.2021-11-04

Track Hangzhou Sumgen Biotech Co., Ltd. automatically

Every clearance here is in the API, with alerts when new ones post.